DrugPatentWatch Database Preview
WAKIX Drug Profile
When do Wakix patents expire, and what generic alternatives are available?
Wakix is a drug marketed by Bioprojet Pharma and is included in one NDA.
The generic ingredient in WAKIX is pitolisant hydrochloride. One supplier is listed for this compound. Additional details are available on the pitolisant hydrochloride profile page.
Summary for WAKIX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 38 |
| Patent Applications: | 19 |
| DailyMed Link: | WAKIX at DailyMed |
Generic Entry Opportunity Date for WAKIX
Generic Entry Date for WAKIX*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Synonyms for WAKIX
| 1-(3-(3-(4-Chlorophenyl)propoxy)propyl)piperidine |
| 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine |
| 1-[3-[3-(4-Chlorophenyl)propoxy]propyl]-piperidinehydrochloride |
| 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine |
| 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine |
| 3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether |
| 362665-56-3 |
| 3973AH |
| 4BC83L4PIY |
| AKOS028108820 |
| API0014072 |
| BCP13114 |
| BDBM50247053 |
| BF2.649 |
| CHEBI:134709 |
| CHEMBL462605 |
| CS-0666 |
| CTK1B6404 |
| D10749 |
| DTXSID30957654 |
| GTPL8924 |
| HBS-101 |
| HMS3743C05 |
| HY-12199 |
| KS-000002GS |
| MFCD18782650 |
| NNACHAUCXXVJSP-UHFFFAOYSA-N |
| Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]- |
| Pitolisant |
| Pitolisant (BF2.649) |
| Pitolisant (USAN/INN) |
| Pitolisant [USAN:INN] |
| SB17037 |
| SCHEMBL117648 |
| TIPROLISANT |
| tiprolisant [USAN] |
| Tirolisant |
| UNII-4BC83L4PIY |
| W-5790 |
| Wakix (TN) |
| ZINC34045468 |
US Patents and Regulatory Information for WAKIX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioprojet Pharma | WAKIX | pitolisant hydrochloride | TABLET;ORAL | 211150-001 | Aug 14, 2019 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Bioprojet Pharma | WAKIX | pitolisant hydrochloride | TABLET;ORAL | 211150-002 | Aug 14, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
